Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 73 of the 107 sources its claims cite were checked for support.

Novel 2-Benzylbenzimidazole Opioids: Emerging Drugs of Abuse and Pharmacological Considerations with Nitazene Analogs

Open access
Maxwell, Mary Kathryn, Anwar, Ahmed I., Hasoon, Jamal, Kaye, Alan D. · 2026 · Current Pain and Headache Reports

Abstract

PURPOSE OF REVIEW: To summarize the developing evidence on novel 2-benzlbenzimidazole opioids (nitazene analogs), including pharmacology, potency, toxicology, management of overdose, and public health issues that are caused by this set of compounds as there is an increasing presence in illicit drug markets. RECENT FINDINGS: Nitazene analogs include those such as isotonitazene, metonitazene, protonitazene, and etonitazene are highly potent mu opioid receptor agonists and are increasingly detected in counterfeit and illicit pharmaceutical products with exposure in other substances including other drugs. Reports from multiple clinical, forensic, and public health investigations have all demonstrated that severe opioid toxicity can be characterized by profound respiratory depression, which is seen in nitazene compounds. Detection remains a central issue with this compound because these derivatives frequently are missed in routine toxicology screening. Nitazene analogs represent a new class of synthetic opioids that are associated with a high overdose risk related to high potency and increased prevalence worldwide. New techniques for overdose reversal include improvements in the pharmacology of opioid antagonists, prolonged and improved monitoring, and advances in life support inside and outside the hospital setting.

Overview

CoChat Summary

TL;DR

This narrative review summarizes the pharmacology, potency, toxicology, detection, and public health impact of 2-benzylbenzimidazole opioids ("nitazenes"), a class of highly potent mu-opioid receptor agonists increasingly found in illicit and counterfeit drug supplies. It emphasizes that routine immunoassay screening frequently misses these compounds, that naloxone remains first-line reversal but may require repeat dosing, and that surveillance and harm-reduction efforts lag behind the market.

Key findings

  • Nitazene analogs are potent mu-opioid receptor agonists; the review's adapted potency table (relative to heroin = 1) lists fentanyl 50, metonitazene 50, protonitazene 100, isotonitazene 250, and etonitazene 500. Etonitazene is separately described as "1000-fold more potent than morphine."
  • In a case series of laboratory-confirmed nitazene poisoning, naloxone successfully reversed toxicity, but repeat naloxone administration was required in approximately 45% of patients receiving naloxone. Experimental data suggest nitazenes dissociate slowly from the mu-opioid receptor and are more resistant to naloxone antagonism than rapidly dissociating opioids.
  • Routine hospital immunoassay panels frequently miss nitazenes due to minimal cross-reactivity with antibodies for morphine, heroin, and fentanyl; definitive identification relies on LC-MS/MS, LC-QTOF-MS, or LC-HRMS. Nitazene test strips detected 28 of 36 nitazene compounds, with false negatives and false positives linked to high caffeine concentrations.
  • Nearly 7,000 nitazene submissions were reported in the U.S. National Forensic Laboratory Information System (NFLIS) between 2019 and 2025; nitazene analogs have also been detected in wastewater samples across multiple countries, and overdoses are reported in the UK, Norway, Australia, and the United States.

Methods

  • Narrative review (no stated systematic search strategy, inclusion criteria, or PRISMA-type methodology) covering pharmacology, potency, clinical toxicology, overdose management, and public health challenges of nitazene analogs.
  • Evidence base is a synthesis of cited in vitro receptor pharmacology, in vivo animal studies, human metabolism studies, clinical case reports and case series, forensic/toxicology surveillance data, and wastewater epidemiology.
  • Potency comparisons are presented in a single adapted table (Table 1) drawing on two cited sources; the text notes potency estimates vary by experimental endpoint (binding affinity, signaling assays, antinociception, behavioral models) and should be treated as approximations.

Limitations

  • Stated in the paper: potency rankings "should be interpreted as approximations rather than absolute values" because estimates vary by experimental endpoint; the review also notes that additional evidence is needed before a longer-acting antagonist such as nalmefene can be recommended to replace naloxone.
  • Evident from the text: as a narrative review without a described search strategy or systematic selection criteria, it is susceptible to selection and reporting bias, and much of the clinical evidence rests on case reports and case series rather than controlled studies.
  • Evident from the text: several key claims (e.g., greater naloxone requirements than fentanyl overdose, prolonged receptor occupancy) are attributed to single studies or small series, and the review does not quantify prevalence trends beyond the NFLIS submission count.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s11916-026-01525-0

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

57 Valid · 8 Not valid · 20 Not checked · 11 Own results and interpretations

49 more claims · 33 with their cited sources checked

Create a free account to see all 96 claims and to verify the 2 references still open.

See all claims — free account
  • It may state two separate claims as one. 42
  • Probably not a substantial claim. 1

Create a free account to see these claims.

Citations

Cites

Show all 48 references

Metadata

Authors
Maxwell, M. K., Anwar, A. I., Hasoon, J., & Kaye, A. D.
Affiliations
  • Louisiana State University (US)
  • The University of Texas Health Science Center at Houston (US)
Corresponding author
Anwar, Ahmed I.
Venue
Current Pain and Headache Reports
Published
2026-07-22
Volume
30
Issue
1
ISSN
  • 1531-3433 (ISSN-L)
  • 1534-3081
OpenAlex
W7170076256
Cited by
0
References
48
FWCI
0.00
Type
journal article
Language
en
Open access
Licence
Locations
  • Current Pain and Headache Reports (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
Keywords
synthetic opioids, isotonitazene, etonitazene, mu-opioid receptor agonists, opioid overdose, respiratory depression, opioid toxicity, illicit drug markets, counterfeit drugs, toxicity screening, overdose reversal, opioid antagonists
MeSH terms
Analgesics, Opioid, Animals, Benzimidazoles, Humans, Opioid-Related Disorders, Illicit Drugs, Drug Overdose

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Novel 2-Benzylbenzimidazole Opioids: Emerging Drugs of Abuse and Pharmacological Considerations with Nitazene Analogs. https://app.cochat.ai/papers/10.1007/s11916-026-01525-0
The paper
Maxwell, M. K., Anwar, A. I., Hasoon, J., & Kaye, A. D. (2026). Novel 2-Benzylbenzimidazole Opioids: Emerging Drugs of Abuse and Pharmacological Considerations with Nitazene Analogs. Current Pain and Headache Reports. https://doi.org/10.1007/s11916-026-01525-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.